Physician profile
Patrick Gerard Reilly
NPI 1164482485
$7,298.69
in general payments reported to CMS, 2019-2025
33 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $159 · 2021: $572 · 2022: $492 · 2023: $1,449 · 2024: $1,564 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,477 · Education: $34.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,476.95 |
| Education | $34.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,707.41 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,087.28 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Insmed, INC. | $394.83 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $340.49 | 2019-2021 | |
| Genzyme Corporation | $295.63 | 2023-2025 | |
| Verona Pharma, INC. | $248.57 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $210.80 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.64 | 2022-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $194.62 | 2021-2024 | |
| Pulmonx Corporation | $192.05 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Resmed Corp | $173.28 | 2024-2025 | |
| Inspire Medical Systems, INC. | $143.73 | 2023-2024 | Inspire |
| Electromed, INC. | $122.83 | 2025 | Smartvest |
| Genentech USA, INC. | $122.33 | 2019 | |
| Boston Scientific Corporation | $104.57 | 2025 | General - Therapies |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $100.08 | 2024 | Lumryz |
| Mylan Specialty L.P. | $70.45 | 2022-2024 | Yupelri |
| Vifor Pharma, INC. | $62.84 | 2024-2025 | Zemaira |
| Actelion Pharmaceuticals US, INC. | $57.86 | 2024-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $55.84 | 2023-2024 | Glassia |
| Baxter Healthcare | $53.28 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Pfizer INC. | $45.63 | 2025 | |
| Amgen INC. | $44.34 | 2022-2025 | Tezspire |
| Philips North America LLC | $41.50 | 2019-2022 | |
| Zoll Respicardia, INC. | $38.15 | 2024-2025 | Remede System |
| Novartis Pharmaceuticals Corporation | $32.70 | 2025 | |
| Merck Sharp & Dohme LLC | $31.83 | 2023 | |
| United Therapeutics Corporation | $27.05 | 2024 | Tyvaso |
| Csl Behring | $23.30 | 2019 | |
| Nabriva Therapeutics, Plc | $20.94 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.56 | 2025 | Alvesco |
| Gilead Sciences, INC. | $18.82 | 2021 | |
| Lilly USA, LLC | $15.46 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.